See more : ADF Group Inc. (DRX.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Praxis Precision Medicines, Inc. (PRAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Praxis Precision Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Far East Fame Line DDB Public Company Limited (FE.BK) Income Statement Analysis – Financial Results
- Cromwell European Real Estate Investment Trust (CWBU.SI) Income Statement Analysis – Financial Results
- LEVERAGE SHARES PUBLIC LIMITED (1SHO.L) Income Statement Analysis – Financial Results
- CleanTech Acquisition Corp. (CLAQR) Income Statement Analysis – Financial Results
- Pang Da Automobile Trade Co., Ltd (601258.SS) Income Statement Analysis – Financial Results
Praxis Precision Medicines, Inc. (PRAX)
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| Gross Profit | 2.45M | -1.17M | -1.59M | -746.00K | -679.00K | -1.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.77M | 155.04M | 120.26M | 44.98M | 29.56M | 18.82M |
| General & Administrative | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Other Expenses | 0.00 | 957.00K | 271.00K | 140.00K | 0.00 | -3.65M |
| Operating Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Cost & Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Interest Income | 3.10M | 0.00 | 271.00K | 140.00K | 193.00K | 92.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.00K |
| Depreciation & Amortization | 432.00K | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| EBITDA | -125.94M | -212.86M | -165.47M | -61.08M | -34.92M | -26.27M |
| EBITDA Ratio | -5,146.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.37M | -214.99M | -167.33M | -61.97M | -35.79M | -22.72M |
| Operating Income Ratio | -5,164.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.10M | 957.00K | 271.00K | 140.00K | 193.00K | -3.68M |
| Income Before Tax | -123.28M | -214.03M | -167.06M | -61.83M | -35.60M | -26.40M |
| Income Before Tax Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -957.00K | -182.00K | -8.00K | -84.00K | 133.00K |
| Net Income | -123.28M | -213.07M | -166.88M | -61.82M | -35.51M | -26.54M |
| Net Income Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| EPS Diluted | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Avg Shares Out | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
| Weighted Avg Shares Out (Dil) | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
Praxis Precision Posts Disappointing Data From Depression Study
Praxis Precision Medicines, Inc. (PRAX) - CEO Marcio Souza on Q1 2022 Earnings Call Transcript
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
Praxis Precision Medicines to Present at Stifel's 4th Annual CNS Day
Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript
12 biotech stocks to consider buying now as prospects for the sector brighten this year
Praxis Precision Medicines to Present at Piper Sandler's 33rd Annual Virtual Healthcare Conference
Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports